News

Video

Dr Yehuda Handelsman on How Insulin Therapy Advances Can Boost Patients' Quality of Life

With new technologies that allow insulin to be delivered much more easily and at a targeted speed, diabetes treatment is less likely to interfere with patients’ lives, explained Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America.

With new technologies that allow insulin to be delivered much more easily and at a targeted speed, diabetes treatment is less likely to interfere with patients’ lives, explained Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America.

Related Videos
Firas El Chaer, MD, smiling during a video interview
Mikael Eriksson, PhD.
Roberto Salgado, MD.
Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson chair in preventative cardiology, Tulane University School of Medicine
Screenshot of an interview with Shaun P. McKenzie, MD
Hans Lee, MD
Don M. Benson, MD, PhD, James Cancer Hospital
Picture of San Diego skyline with words ASH Annual Meeting 2024 and health icons overlaid on the bottom
Robin Glasco, MBA
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Related Content
FDA Approves First Generic Daily GLP-1 Injection for Type 2 Diabetes
December 23rd 2024

FDA Approves First Generic Daily GLP-1 Injection for Type 2 Diabetes

Rose McNulty
The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients with type 2 diabetes as a complement to diet and exercise.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
FDA website | Image credit: Postmodern Studio – stock.adobe.com
December 20th 2024

FDA Rejects Sotagliflozin for Type 1 Diabetes; Lexicon Shifts Focus

Hayden E. Klein
The FDA issued a complete response letter for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control.
Managed Care Cast
December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi
Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Dr Yehuda Handelsman
December 20th 2024

Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management

Brooke McCormick
In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.
Heart pulse, beat concept in atrial fibrillation | image credit: martialred - stock.adobe.com
December 19th 2024

Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab

Kyle Munz
Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo